CDK 4/6 inhibitors
What are CDK 4/6 inhibitors?
CDK4/6 inhibitors are a class of drugs that target particular enzymes, called CDK4 and CDK6. CDK stands for cyclin-dependent kinase, and it is an enzyme that is important for cell division. CDK4/6 inhibitors interrupt signals that stimulate the proliferation of malignant (cancerous) cells.
Certain cancers, for example, hormone receptor-positive breast cancer, are more likely to have disturbances in CDK4/6, and CDK 4/6 inhibitors may form part of the treatment protocol. Most often, CDK4/6 inhibitors are given synergistically with hormonal therapy (such as an aromatase inhibitor or fulvestrant), although the CDK4/6 inhibitor abemaciclib may be used alone to treat hormone receptor-positive, HER2-negative metastatic breast cancer in pre-treated patients.
Research suggests CDK4/6 inhibitors may increase the time people have before cancer spreads. More evidence is needed to determine their impact on overall survival.
Common side effects include fatigue and gastrointestinal disturbances, such as nausea, diarrhea, and vomiting. Bone marrow suppression resulting in neutropenia and leukopenia may also occur, although anemia and thrombocytopenia are less common. In general, the side effects associated with CDK4/6 inhibitor therapy are less severe than those experienced with chemotherapy.
List of CDK 4/6 inhibitors:
|Drug Name||Avg. Rating||Reviews|
Generic name: palbociclib
Generic name: ribociclib
Generic name: abemaciclib
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|
Medical conditions associated with CDK 4/6 inhibitors:
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.